Cancer Biomarkers in Body Fluids

doi:10.3390/books978-3-0365-6648-1

Format

Hardback

License and Copyright

Keywords

primary breast cancer; circulating nucleosomes; circulating tumor cells; plasminogen activator inhibitor-1; cytokines; prostate cancer; breast cancer; circulating tumor cells; treatment decisions; exosomes; molecular composition; cancer pathogenesis; diagnostics; therapeutics; leptomeningeal metastasis; cerebrospinal fluid; extracellular vesicle; biomarker; RNA sequencing; small non-coding RNA; microRNA; exosomes; prostate cancer; exo-oncomiRNAS; TWEAK; semen; rheumatoid factor; autoimmunity; autoantibodies; cancer; biomarker; predictive biomarker; prognostic biomarker; cancer progression; cancer development; immunotherapy; cancer susceptibility; tumor recurrence; tumor load; fecal immunochemical test (FIT); colonoscopy; flexible sigmoidoscopy; liquid biopsy; mRNA; microRNA; ctDNA; proteins; extracellular vesicles; biomarkers; exosome; extracellular vesicles; lung cancer; miRNA; plasma; serum; volatile organic compounds (VOCs); gas chromatography (GC); mass spectrometry (MS); headspace solid phase microextraction (HS-SPME); breast cancer biomarkers; principal component analysis (PCA); linear discriminant analysis (LDA); principal component regression (PCR); liquid biopsy; cfDNA; hereditary and familial pancreatic cancer; somatic mutation profiling; potentially druggable genes; uveal melanoma; circulating tumor DNA; next generation sequencing; PKC inhibitor; liquid biopsy; treatment; response; melanoma; ovarian cancer; lipidomics; lipid; prognosis; ceramide; phospholipid; plasmalogen; biomarker; patient stratification; outcome; personalized medicine; neuroblastoma; immune monitoring; anti-GD2; IL-2; GM-CSF; ASCT; immunotherapy; dinutuximab; exosomes; cancer; liquid biopsy; biomarkers; immunotherapy; anti-PD-1; melanoma; urothelial cancer; immune monitoring; blood biomarkers; NETs; disease modelling; machine learning; metabolic signaling; molecular pathways; plasma metabolites; diagnostic biomarkers; liquid biopsy; urine; urine liquid biopsy; DNA; mRNA; microRNA; sncRNA; bladder cancer; metabolic pathways; metabolism; metabolomics; epigenetics; biomarkers; miRNAs; epigenetic biomarkers; cancer; DNA methylation; micro-RNAs; human papillomavirus; oropharyngeal squamous cell carcinoma; treatment de-escalation; patient stratification; E7 oncoprotein; HPV DNA; HPV antibodies; ELISA; cancer biomarkers; prostate cancer; liquid biopsy; prognosis; diagnosis; early detection; n/a; lung cancer; early diagnosis; biomarkers; liquid biopsy; circulating tumor cells; lung cancer; early diagnosis; cancer biomarkers

Accessibility Information

We are working as quickly as possible to make a fully accessible version of this title. Thank you for your patience.

Reprint

Download Flyer

Cancer Biomarkers in Body Fluids

Edited by

March 2023

490 pages

ISBN 978-3-0365-6649-8 (Hardback)
ISBN 978-3-0365-6648-1 (PDF)

https://doi.org/10.3390/books978-3-0365-6648-1

Free Download (PDF)

This is a Reprint of the Special Issue Cancer Biomarkers in Body Fluids that was published in

Biology & Life Sciences

Summary

Liquid biopsy shows promise for cancer screening and diagnostics. This reprint collects recent scientific literature on the identification and application of tumor biomarkers in biological fluids to improve the diagnosis of cancer and the identification of optimal therapeutic strategies.

The recommendations have been generated using an AI system.

Cancer Biomarkers in Body Fluids

Related Books

Molecular Biomarkers of Tumors

Cancer Biomarker Research and Personalized Medicine

Novel Biomarkers of Gastrointestinal Cancer

Biomarkers Used for the Diagnosis of Diseases

New Prognostic and Predictive Markers in Cancer Progression